Diagnostic Value of Contrast-Enhanced Ultrasonography With SonoVue in the Differentiation of Benign and Malignant Breast Lesions: A Meta-Analysis

Lu, Jianghao; Zhou, Peng; Jin, Chen; Xu, Lifeng; Zhu, Xiaomin; Lian, Qingshu; Gong, Xun

doi:10.1177/1533033820971583

Cited by 8 publications

(5 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MVD is associated with a poorer prognosis in breast and kidney cancer patients (27,28) and correlates with the depth of tumor invasion (29). Intravenous CEU has been used widely to assess tumor angiogenesis in vivo (10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20) and provides detailed information about the vascularity and blood flow kinetics in normal and pathologic tissues. Previous studies have shown that malignant ovarian masses generally have a greater PI compared with benign masses (17-20).…”

Section: Discussionmentioning

confidence: 99%

“…Tumor angiogenesis is necessary for tumor growth and is an independent prognostic indicator for survival in cancer patients, such as in ovarian carcinoma ( 8 , 9 ). Advances in contrast enhanced ultrasonography (CEU) have enabled the characterization of tumor vascularity, such as in hepatic ( 10 , 11 ), breast ( 12 , 13 ), gastric ( 14 ), prostate ( 15 ), and cardiac masses ( 16 ). Several studies have reported that qualitative ( 17 ) and quantitative ( 18 – 20 ) CEU can improve the performance of sonography in distinguishing benign adnexal masses from malignancy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Contrast-enhanced ultrasonography for differential diagnosis of adnexal masses

Shentu

Zhang²,

Gu³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundQuantitative contrast-enhanced ultrasonography parameters are affected by various factors. We evaluated corrected quantitative contrast enhanced ultrasonography in differentiating benign adnexal tumors from malignant tumors.MethodsPatients with adnexal masses who underwent conventional and contrast-enhanced ultrasonography were included. Contrast-enhanced ultrasonography parameters such as base intensity, arrival time, peak intensity, time to peak intensity, ascending slope, and descending slope were measured. Corrected (time to peak intensity − arrival time) mass/(time to peak intensity − arrival time) uterus and (peak intensity − base intensity) mass/(peak intensity − base intensity) uterus were calculated. Lesions were confirmed by pathologic examination of surgical specimens.ResultsThis study included 31 patients with 35 adnexal lesions including 20 (57.10%) benign and 15 (42.90%) malignant lesions. The corrected contrast-enhanced ultrasonography quantitative parameters in lesions were statistically different between malignant and benign groups (P<0.05). The optimal cut-off value for (time to peak intensity − arrival time) mass/(time to peak intensity − arrival time) uterus, ascending slope, and (peak intensity − base intensity) mass/(peak intensity − base intensity) uterus, and descending slope for differentiating malignant adnexal masses from benign tumors were 1.05 (area under curve: 0.93, P<0.05), 1.11 (area under curve: 0.83, P<0.05), 0.82 (area under curve: 0.73, P<0.05), and −0.27 (area under curve: 0.66, P=0.16), with sensitivity and specificity of 93.33% and 85.00%, 86.67% and 75.00%, 86.67% and 60.00%, and 54.55% and 66.67%, respectively.ConclusionsCorrected contrast-enhanced ultrasonography parameters provide practical differential diagnosis value of adnexal lesions with high reliability for sonologists.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Contrast-enhanced ultrasonography for differential diagnosis of adnexal masses

Shentu

Zhang²,

Gu³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…11 Contrast-enhanced ultrasound (CEUS) could evaluate angiogenesis quantitatively and differentiate between benign and malignant breast diseases. 12 BC is a highly heterogeneous malignant tumor, 13 but simple differentiation between benign and malignant characteristics is insufficient to allow the accurate diagnosis and appropriate treatment of BC, given that different molecular subtypes of BC require different treatment regimens. The St. Gallen Consensus 2013 14 classified the molecular subtypes of BC as LA, LB, H2, and TN.…”

mentioning

confidence: 99%

“…The newly formed pathological microvessels differ from normal blood vessels, with increased permeability and lack of normal vascular regulation processes, potentially leading to changes in blood perfusion 11 . Contrast‐enhanced ultrasound (CEUS) could evaluate angiogenesis quantitatively and differentiate between benign and malignant breast diseases 12 . BC is a highly heterogeneous malignant tumor, 13 but simple differentiation between benign and malignant characteristics is insufficient to allow the accurate diagnosis and appropriate treatment of BC, given that different molecular subtypes of BC require different treatment regimens.…”

mentioning

confidence: 99%

Association Between Contrast‐Enhanced Ultrasound Characteristics and Molecular Subtypes of Breast Cancer

Wen

Kong

Zhang

et al. 2021

J of Ultrasound Medicine

View full text Add to dashboard Cite

Objective This study aimed to investigate the correlation between contrast‐enhanced ultrasound (CEUS) features and molecular subtypes of breast cancer (BC). Methods A total of 116 patients (116 lesions) with pathologically diagnosed BC who received conventional ultrasound and CEUS before surgery were enrolled in this study. BC molecular subtypes were identified by postoperative pathological and immunohistochemical analysis as Luminal A (LA), Luminal B (LB), HER2 (H2) over‐expression, and triple‐negative (TN). Qualitative and quantitative CEUS characteristics were analyzed by one‐way analysis of variance (continuous variables) or Pearson's χ2 test or Fisher's exact probability method (categorical variables). Results There were significant differences in enhancement speed and enhancement degree among the four subtypes (P < .05). The area under the curve (AUC), time to peak (TTP), and peak intensity (PI) differed among the four subtypes (P < .05). The AUC of the LA subtype (305.1 ± 188.4) was significantly smaller compared with the H2 (535.7 ± 222.0, P = .007) and TN subtypes (496.6 ± 254.7, P = .019). In addition, TTP was shorter in the H2 subtype (19.8 ± 4.9) compared with the other subtypes, and was significantly shorter than in the LA subtype (26.3 ± 7.2, P = .008) and LB subtype (23.1 ± 6.7, P = .036). The PI of the LA subtype (4.7 ± 2.3) was significantly lower than that of the LB (6.6 ± 2.3, P = .027), H2 (7.4 ± 2.2, P = .005), and TN subtypes (6.9 ± 2.6, P = .014). Conclusions CEUS features differed significantly among different molecular subtypes of BC. The enhancement patterns and parameters may be important predictive features of different subtypes of BC.

show abstract

“…However, only a few studies thus far have conducted qualitative or quantitative analyses of the differential diagnosis of pelvic tumors. Furthermore, there is a crossover of quantitative indices in benign and malignant lesions and a lack of a uniform standard for each index ( 8 , 9 ). Qualitative analysis is also susceptible to considerable subjective and operational differences, which limits its clinical application ( 10 ).…”

Section: Introductionmentioning

confidence: 99%

Clinical value of quantitative analysis of contrast-enhanced ultrasonography in the differential diagnosis of benign and malignant pelvic tumors

Fan,

Zhang,

Wang

et al. 2023

Quant Imaging Med Surg

View full text Add to dashboard Cite

Background Cervical cancer, endometrial cancer, and ovarian cancer are among the top 10 most common cancers in women, with ovarian cancer in particular being considered a “silent killer”. Therefore, early detection, diagnosis, and treatment constitute important means of care for women’s health. This study investigated the clinical value of the quantitative analysis of contrast-enhanced ultrasonography (CEUS) in the differential diagnosis of benign and malignant pelvic tumors. Methods CEUS was performed on 151 patients with pelvic masses. Subsequently, a qualitative diagnosis was completed using the image enhancement features and tumor parameters. A multiparametric analysis of CEUS images was performed, which included the following parameters: arrival time (AT), time to peak (TTP), peak intensity (PI), and ascent slope (AS). In addition, the qualitative diagnostic efficiency of CEUS was assessed in a multiparametric analysis, and the results were compared with pathological findings. Results The patients in the malignant group were older (P=0.001) and had larger lesion PI values (P<0.01) than those in the benign group. The PI difference (PI d ) and the AS difference (AS d ) showed statistical differences (P<0.01) between the myometrium and lesion tissues in the same patient. Moreover, the PI d and AS d showed the largest receiver operating characteristic (ROC) curve and area under the ROC curve (AUC), with sensitivities of 90.9% and 91.7% and specificities of 86.4% and 72.5%, respectively. Conclusions The quantitative analysis of CEUS provides a new, simpler, and more accurate method for the differential diagnosis of benign and malignant pelvic masses in clinical practice. The sensitivities and specificities of PId and ASd were higher compared to other parameters from the same patient.

show abstract

Diagnostic Value of Contrast-Enhanced Ultrasonography With SonoVue in the Differentiation of Benign and Malignant Breast Lesions: A Meta-Analysis

Cited by 8 publications

References 40 publications

Contrast-enhanced ultrasonography for differential diagnosis of adnexal masses

Contrast-enhanced ultrasonography for differential diagnosis of adnexal masses

Association Between Contrast‐Enhanced Ultrasound Characteristics and Molecular Subtypes of Breast Cancer

Clinical value of quantitative analysis of contrast-enhanced ultrasonography in the differential diagnosis of benign and malignant pelvic tumors

Contact Info

Product

Resources

About